10-Q: Surrozen Reports Q1 2026 Financials, Focus on Ophthalmology Pipeline

Surrozen, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $127.5 million and continued investment in its Wnt pathway-modulating therapeutics for ophthalmic diseases.

Summary

• Surrozen reported a net loss of $127.5 million for the first quarter of 2026, compared to a net loss of $27.0 million in the same period of 2025.
• Total revenue for Q1 2026 was $5.0 million, primarily from collaboration and license revenue, a significant increase from $0.983 million in Q1 2025.
• Research and development expenses increased by 42% to $9.3 million, while general and administrative expenses rose by 54% to $6.1 million.
• The company had $106.9 million in cash and cash equivalents as of March 31, 2026, which management believes is sufficient for at least the next 12 months.
• The company is developing SZN-8141 and SZN-8143 for retinal diseases like diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD).
• A milestone payment of $5.0 million was received from Boehringer Ingelheim in April 2026 related to the CLA for SZN-413.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss and operating expenses, despite positive developments in collaboration revenue and cash position. The ongoing need for capital and lack of approved products remain key concerns.

Positives

• Collaboration and license revenue increased significantly to $5.0 million in Q1 2026, driven by a milestone payment from Boehringer Ingelheim.
• Cash and cash equivalents increased to $106.9 million, providing a runway of at least 12 months.
• The company received a $5.0 million milestone payment from Boehringer Ingelheim in April 2026 for positive IND-enabling toxicology study results for SZN-413.
• Progress in advancing its ophthalmology pipeline with candidates like SZN-8141 and SZN-8143.

Negatives

• Net loss widened significantly to $127.5 million in Q1 2026 from $27.0 million in Q1 2025.
• Operating expenses increased substantially, with R&D up 42% and G&A up 54%.
• The company continues to incur significant operating losses and expects to do so for the foreseeable future.
• The company anticipates the need to raise additional capital to fund its long-range business plan.
• The fair value of tranche liability increased significantly to $235.5 million, and warrant liabilities increased to $148.9 million.

Risks

• The company has a history of losses and expects to continue incurring significant losses, with no guarantee of achieving profitability.
• Substantial additional funds are needed to advance product candidates, and there is no guarantee of securing sufficient future funding.
• None of the company's product candidates have received regulatory approval.
• Clinical development activities are lengthy, expensive, and uncertain, with a high risk of failure.
• The company relies on third parties for preclinical studies and clinical trials, who may not perform satisfactorily.
• Manufacturing of product candidates is complex, and the company and its third-party manufacturers may encounter production difficulties.
• Competition from other entities developing product candidates for similar diseases could adversely affect the company's ability to commercialize its products.
• The company's stock price is likely to be volatile.
• A few stockholders control a significant portion of voting rights, which could adversely affect the company or its stockholders.
• International trade policies, including tariffs, may adversely affect the business, financial condition, results of operations, and prospects.

Future Outlook

The company expects to continue incurring significant operating losses and anticipates the need to raise additional capital to fund its long-range business plan, including advancing its product candidates through clinical development and regulatory submissions. Management believes current cash is sufficient for at least the next 12 months, with potential additional funding from the second tranche of the 2025 PIPE if certain milestones are met.

Management Comments

• Management believes that the existing cash and cash equivalents are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its unaudited condensed consolidated financial statements.
• If the Company's cash burn is greater than anticipated, the Company could use its capital resources sooner than expected which may result in the need to reduce future planned expenditures and/or raise additional capital to continue to fund the operations.

Industry Context

StockSavvy.ai notes that Surrozen's focus on the Wnt pathway for ophthalmology aligns with emerging trends in regenerative medicine and targeted therapies. The significant increase in R&D spending reflects the capital-intensive nature of drug development in the competitive biotech sector.

Legal Proceedings

• The company is not currently a party to or aware of any proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Research Collaboration Agreement with TCGFB, Inc. (terminated November 2025).
• Sublease agreement with Nura Bio, Inc. for office and laboratory space.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• The company's ability to achieve profitability and long-term viability depends on successful product development and capital raising.
• Employees' continued employment and compensation are subject to the company's financial performance and funding needs.

Next Steps

• Submit an IND for SZN-8141 in the second half of 2026.
• Continue advancing SZN-8141 and SZN-8143 through development.
• Evaluate research-stage programs for other ophthalmic indications.
• Potentially raise additional capital through equity or debt offerings.

Key Dates

Recommendation

While Surrozen shows progress in its pipeline and has secured milestone payments, the significant increase in net loss and operating expenses, coupled with the ongoing need for substantial capital, warrants a cautious approach. The company's future success is heavily dependent on clinical trial outcomes and its ability to secure further funding, making it a speculative investment at this stage. A 'hold' recommendation reflects this balance of potential upside and significant risk.

Keywords

Surrozen, 10-Q, Biotechnology, Ophthalmology, Wnt Pathway, Clinical Trials, Drug Development, SEC Filing, Financial Results, Net Loss, Collaboration Revenue